BOSTON, April 26, 2016 /PRNewswire/ -- ORIG3N, Inc., a pioneer in the field of regenerative medicine, today announced the formal opening of its new headquarters and laboratory in Boston's Seaport District, at 27 Drydock Avenue within the Innovation and Design Building. ORIG3N's new expanded facility will provide state-of-the-art functionality to sustain collaborative research programs that support ORIG3N's cellular models called LifeSystems™, as well as the company's product development and commercial activities.
Founded in 2014 by serial entrepreneurs Robin Y. Smith, CEO and Kate Blanchard, COO, ORIG3N uses iPSC technology to accelerate the future of medicine, including the pace of drug development, to overcome the trial-and-error approach common today. ORIG3N is the only biotechnology company that is crowdsourcing blood samples creating a new approach to the understanding and treatment of a variety of diseases.
ORIG3N builds and maintains the world's largest crowdsourced biorepository of induced pluripotent stem cells (iPSCs) called LifeCapsule™. The new facility will help accelerate the next stage of evolution with iPSC technology.
"Regenerative medicine is at the same stage today as the Internet was in 1993. We are on the verge of seeing huge advances in this technology and as part of our mission we are making large and diverse patient cohorts available to researchers while at the same time educating patients on what this technology is," said Smith, in addressing an audience that included government officials and representatives from the biotech and life sciences community. "Being in Boston enables our organization to bring our technology to the epicenter of biotech research in the US."
"The foundation for the regenerative medicine revolution requires unhindered access to patient samples," adds Blanchard. "LifeCapsule has grown exponentially by directly engaging with consumers and patients worldwide. The remarkable growth of LifeCapsule has given ORIG3N the unique ability to create a living snapshot of humanity."
In attending the opening, Mayor Martin J. Walsh noted, "ORIG3N is a great fit for the Innovation District and our city's biotechnology and life sciences community, and we are proud to welcome them to Boston. Their work in studying rare, genetically-inherited diseases will have a huge impact on the future of medicine. ORIG3N's future is bright as they continue to expand and grow their partnerships, and we are excited that they see Boston as the best place to succeed."
About ORIG3N, Inc.
ORIG3N is leading a transformation of the understanding and treatment of rare, genetically-inherited diseases. We've established the world's largest crowdsourced cell repository to better understand the cellular and molecular foundations of disease. The cells are ever-renewing and give rise to a living database of humanity we call LifeCapsule. Thousands of people have already contributed to advancing the future of healthcare—and to safeguarding their own future health. The founders are serial entrepreneurs whose previous venture, ArtusLabs, was acquired by PerkinElmer in 2011.
For more information, visit www.orig3n.com.
Contact: Rebecca LeWinter, (973) 280-7582, [email protected]
SOURCE ORIG3N, Inc.